Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, October 30, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Almac Offering TruSight Tumor Profiling Next-Generation Sequencing Service
Monday, September 30, 2013
TruSight Tumor™ panel is specifically designed for use with FFPE samples.

Almac Launches SupplyTraQ™ Technology Solution
Tuesday, September 24, 2013
Online tool enables more cost-efficient and accurate reconciliation and reporting.

Aptiv Solutions Launches ADDPLAN® DF
Monday, September 23, 2013
An innovative software for optimizing dose selection in phase 2 trials.

Smooth Drug Development Selects CRO Starter Kit™ CTMS by Flex Databases
Monday, September 23, 2013
Flex Databases to release an electronic data capture (EDC) product in Q4 2013.

Almac Launches Reusable Shipper Option for Temperature-Controlled Distribution
Friday, September 20, 2013
Reusable shippers greatly improve environmental impact and provide cost efficiencies.

New Partnership to Improve Clinical Trial Site Evaluation
Thursday, September 19, 2013
iCTRS partners with ViS Research to help trial planners benefit from a better, more efficient site selection process to accelerate development of much-needed medicines.

Stiris Research Selects CRO Starter Kit™ CTMS by Flex Databases
Tuesday, September 17, 2013
Flex CRO Starter Kit™ manage both internal and external processes of a CRO.

BIOTRONIK Releases Line-Extension of Orsiro Hybrid Drug Eluting Stent
Tuesday, September 03, 2013
The highly deliverable Orsiro stent is now available in lengths up to 40 mm to address a wider range of lesions.

OCT are Expanding the Use of the CTMS Platform with Flex Databases
Thursday, August 29, 2013
Expansion to implement the workflow management tool.

<< 3 4 5 6 7 8 9 >>
Showing Results 51 - 60 of 295
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv